J Eur Acad Dermatol Venereol . Rapidly progressive alopecia areata totalis in a Covid-19 patient, unresponsive to tofacitinib

[tetano]

J Eur Acad Dermatol Venereol


. 2021 Feb 15.
doi: 10.1111/jdv.17170. Online ahead of print.
Rapidly progressive alopecia areata totalis in a Covid-19 patient, unresponsive to tofacitinib


S Berbert Ferreira[SUP] 1 2 [/SUP], M F R Gavazzoni Dias[SUP] 3 [/SUP], R Berbert Ferreira[SUP] 2 4 [/SUP], A C Neves Neto[SUP] 4 [/SUP], R M Tr?eb[SUP] 5 6 [/SUP], O Lupi[SUP] 7 8 [/SUP]



Affiliations

• PMID: 33587766
• DOI: 10.1111/jdv.17170

Abstract

Alopecia areata (AA) is a common autoimmune disease characterized by non-scarring hair loss. (1) Tofacitinib is an effective oral JAK 1/3 inhibitor that can block IL-2, IL-7 and IL-6 and is reported as an option for alopecia areata treatment.(2,3) Though some JAK inhibitors are possible new treatments for severe acute respiratory syndrome coronavirus disease, no treatment of Covid-19 with tofacitinib has been reported to date and the withdrawal of the drug in patients with alopecia areata that become infected with the virus, is controversial.

Keywords: Alopecia Areata; Anti-JAK; COVID-19; Corona Virus; Janus Kinase Inhibitor; SARs COV 2; Tofacitinib.